Trifluridine/Tipiracil (TAS-102)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Trifluridine/Tipiracil (TAS-102), covering 2025-03-12 to 2025-03-12. Get the full timeline:
Most recent: Clinical Trial Update: Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer [Phase 2]